Evidence map›Paper›PMID 24645687›Full record

Trial reportJournal of comparative effectiveness research2014

Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancer.

Joshua A Roth, Mark E Bensink, Paul V O'Donnell, Ephraim J Fuchs, Mary Eapen, Scott D Ramsey

Registry-linked trialOpen access · greenAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of comparative effectiveness research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01597778 (A Multi-Center, Phase III, Randomized Trial of RIC and Transplantation of), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01597778 phase3completednot on this map

A Multi-Center, Phase III, Randomized Trial of RIC and Transplantation of (dUCB) Versus HLA-Haplo Related Bone Marrow for Patients With Hematologic Malignancies.(BMT CTN #1101)

TypeinterventionalSponsorMedical College of WisconsinRan2012 to 2020Enrolled368ConditionsAcute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Burkitt's Lymphoma, Follicular LymphomaArmsHaploidentical Bone Marrow Transplant, Double Umbilical Cord Blood Transplant
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Review
  3. Umbilical cord blood: The promise and the uncertainty.Stem cells translational medicine · 2020
    Review
  4. Administrative Claims Data for Economic Analyses in Hematopoietic Cell Transplantation: Challenges and Opportunities.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016
    Review
  5. The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Joshua A RothPublic Health Sciences Division, Fred Hutchinson Cancer Research Centre, 1100 Fairview Avenue North, Seattle, WA 98109, USA.
Mark E Bensink
Paul V O'Donnell
Ephraim J Fuchs
Mary Eapen
Scott D Ramsey
Fred Hutch Cancer Center · USJohns Hopkins University · USKaiser Permanente Washington Health Research Institute · USMedical College of Wisconsin · USUniversity of Washington · US

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
Easy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8M
Hutchinson Center as Lead Academic Participating Site (U10)U10CA180828 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI APPELBAUM, FREDERICK · 2014 to 2018
$3.0M
BMT CTN 1101 Ancillary Cost-Effectiveness AnalysisR01HL116291 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI RAMSEY, SCOTT D. · 2012 to 2015
$1.7M
Health Care Improvement for Aging WomenT32AG027677 · NIA · KAISER FOUNDATION HEALTH PLAN OF WASHINGTON · PI LACROIX, ANDREA Z. · 2007 to 2016
$1.4M
University of Michigan Core Clinical Center for BMT Research NetworkU10HL069330 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI YANIK, GREGORY A · 2011 to 2016
$959k
Enhancing the Safety of Allogeneic TransplantationU10HL069290 · NHLBI · UNIVERSITY OF MINNESOTA · PI WEISDORF, DANIEL J · 2011 to 2016
$931k
Core Clinical Consortium for Blood and Marrow Transplant Clinical Trials NetworkU10HL069301 · NHLBI · UNIVERSITY OF FLORIDA · PI WINGARD, JOHN R. · 2011 to 2016
$882k
Translational Research in Blood and Marrow TranslplantationU10HL069310 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI JONES, RICHARD J · 2011 to 2016
$777k
NCI NIH HHS U10 CA180828NCI NIH HHS U24 CA076518NHLBI NIH HHS R01 HL116291NHLBI NIH HHS R01HL116291-01NHLBI NIH HHS U10 HL069290NHLBI NIH HHS U10 HL069294NHLBI NIH HHS U10HL069294NHLBI NIH HHS U10 HL069301NHLBI NIH HHS U10 HL069310NHLBI NIH HHS U10 HL069330NIA NIH HHS T32 AG027677
6 · The paper itself

Abstract

backgroundBMT CTN 1101 is a Phase III randomized controlled trial evaluating the comparative effectiveness of double unrelated umbilical cord blood (dUCB) versus HLA-haploidentical related donor bone marrow (haplo-BM) donor cell sources for blood or bone marrow transplantation (BMT) in patients with hematologic malignancies. Herein, we present the rationale, design and methods of the first cost-effectiveness analysis to be conducted alongside a BMT trial.

methodsConsenting patients will provide health insurance information to allow calculation of direct medical costs from reimbursement records, and will provide out-of-pocket costs, time costs and health-related quality of life measures through an online survey. These outcomes will inform a cost-effectiveness analysis comparing dUCB and haplo-BM donor cell sources from patient, payer and societal perspectives.

conclusionNovel approaches may significantly change the cost, outcomes or availability of BMT. The results of this analysis will be the first to provide a comprehensive evaluation of the comparative effectiveness of these approaches from multiple perspectives.

Indexed as

AdolescentAdultAgedBone Marrow TransplantationComparative Effectiveness ResearchCord Blood Stem Cell TransplantationCost-Benefit AnalysisFemaleHealth Care CostsHealth ExpendituresHematologic NeoplasmsHumansMaleMiddle AgedQuality of LifeYoung Adult

Identifiers

PMID24645687
PMCPMC4036637
OpenAlexW2111180648

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.